Trials / Completed
CompletedNCT00400348
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with recurrent or resistant epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panzem Nanocrystal Colloidal Dispersion (NCD) | Panzem NCD 1,000 mg, four times daily for 28 consecutive days |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2008-08-01
- Completion
- 2008-11-01
- First posted
- 2006-11-16
- Last updated
- 2008-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00400348. Inclusion in this directory is not an endorsement.